Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Trial of Iseganan in Prevention of Ventilator-Associated Pneumonia

This study has been terminated.
Sponsor:
Information provided by:
IntraBiotics Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00118781
First received: July 1, 2005
Last updated: July 11, 2005
Last verified: July 2005

July 1, 2005
July 11, 2005
September 2003
Not Provided
The primary objectives of this trial are to evaluate the safety and efficacy of iseganan when administered to intubated patients receiving mechanical ventilation.
Same as current
Complete list of historical versions of study NCT00118781 on ClinicalTrials.gov Archive Site
  • The secondary objectives of this trial are to compare patients receiving iseganan to patients receiving placebo on the following: VAP-free survival through Day 21
  • Days alive and free of parenteral antibiotic use through Day 14
  • Days alive and free of mechanical ventilation through Day 14
Same as current
Not Provided
Not Provided
 
Trial of Iseganan in Prevention of Ventilator-Associated Pneumonia
Randomized, Double-Blind, Placebo-Controlled, Multinational Phase 3 Trial Of Iseganan In Prevention Of Ventilator-Associated Pneumonia

This is a multinational, double-blind, placebo-controlled trial designed to assess whether iseganan, applied topically to the oral cavity, can prevent ventilator-associated pneumonia among patients who are intubated and mechanically ventilated and survive for up to 14 days.

Patients will be randomized and receive their first dose of Study Drug within 24 hours of oral/nasal intubation and the initiation of mechanical ventilation. The Study Period will begin with the first administration of Study Drug (Study Day 1). Three mL of Study Drug (9 mg iseganan or matching placebo) will be applied to all visible surfaces in the oral cavity and the oral portion of the endotracheal tube (for non-tracheostomy patients) every 4 hours through Study Day 14, or until the diagnosis of microbiologically-confirmed pneumonia (based on central laboratory results) or extubation, whichever occurs first.

All patients will be evaluated for clinically defined pneumonia at least once daily and, if diagnosed, blood specimens will be collected and cultured, and a bronchoscopic alveolar lavage (BAL) specimen (for intubated patients) or a respiratory secretion specimen (for extubated patients) will be obtained PRIOR to initiating or changing any systemic antimicrobial therapy.

Interventional
Phase 2
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Pneumonia
Drug: iseganan hydrochloride
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
900
June 2004
Not Provided

Inclusion Criteria:

  • Greater than or equal to 18 years of age
  • Orally/nasally intubated and receiving mechanical ventilation for <24 hours prior to scheduled randomization and administration of the first dose of Study Drug, and in the judgment of the attending physician, expected to remain intubated and mechanically ventilated for at least 48 hours
  • Expected to survive for at least 21 days and to remain at the investigational site and not transferred to another institution while intubated during the 21-day study period
  • Willing and able to provide written informed consent, or if unconscious or have altered sensorium, have a surrogate provide written informed consent as approved by the institution
  • Negative pregnancy test within 7 days prior to randomization if a female of childbearing potential (Negative pregnancy test results [urine or serum] obtained for reason other than the purposes of this study are acceptable.)

Exclusion Criteria:

  • Current diagnosis of pneumonia (Patients currently receiving antibiotics for treatment of pneumonia and patients who meet the study definition of clinically defined pneumonia at the time of screening will be excluded.)
  • Absolute neutrophil count less than 1000/mm3
  • Human immunodeficiency virus infection with a last known CD4 count less than 500/mm3
  • Recipient of organ transplantation and receiving immunosuppressive therapy
  • Current hematologic malignancy
  • Previously documented cystic fibrosis
  • Severe cranio-facial trauma or other medical condition expected to require imminent tracheostomy
  • Patient, patient’s family and/or physician not in favor of aggressive medical management or presence of an advanced directive to withhold life-sustaining treatment
  • Moribund state or expected to survive less than 21 days due to an uncorrectable medical condition
  • Participation in a clinical trial of any unlicensed drug, biologic or device within 30 days prior to the first dose of study drug
  • Concurrent participation in a clinical trial of any unlicensed drug, biologic or device.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00118781
09-002
Not Provided
Not Provided
IntraBiotics Pharmaceuticals
Not Provided
Study Chair: Marin Kollef, MD Barnes-Jewish Hospital, Washington University School of Medicine
IntraBiotics Pharmaceuticals
July 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP